Specifica Announces Delivery of Exclusive Antibody Library Platform to UCB

Specifica Announces Delivery of Exclusive Antibody Library Platform to UCB.

Specifica, a company specializing in revolutionizing antibody discovery and creating antibody libraries, has announced the delivery of an exclusive antibody library platform, called the Generation 3 Library Platform, to UCB, a global biopharmaceutical company focused on the discovery and development of innovative medicines for people suffering from severe diseases of the immune system and the central nervous system.

This library provides a new tool, which can be used alongside their existing platforms and technologies, and enhances their therapeutic antibody discovery capabilities. Kenneth Sharples, CEO and co-founder of Specifica states that, “Specifica’s Generation 3 Library Platform has quality built-in by design. Antibodies from our Generation 3 Platform have few liabilities, and over 80% behave as well as, or better, than the best therapeutic antibodies.”

Specifica specializes in the creation of exceptional antibody libraries, using next-generation sequencing for quality control at all steps of construction and validation. The company ensures high diversity standards by counting the number of different antibodies in each Specifica library. Libraries with high guaranteed diversities mean more antibodies, recognizing more epitopes, with better affinities against targets.

Each Generation 3 Library Platform Specifica provides to its partners is exclusive to that partner, created from unique donor sets not used for any other library, guaranteeing each supplied Generation 3 Library Platform is one of a kind.

In addition to providing unique libraries for platform transfers, Specifica also uses its in-house library to carry out discovery services for partners.

To learn more about Specifica, visit the company’s website at www.specifica.bio.

To read the entire article see the Specifica press release: Specifica Delivers Antibody Platform To UCB  To Speed Up Development Of New Therapeutics